Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

Published:2018-08-02 Issue:7 Volume:48 Page:713-722
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Gagnière Charlotte¹,Bourrier Anne²,Seksik Philippe²^ORCID,Gornet Jean-Marc²,DeWit Olivier³,Nancey Stephane⁴,Altwegg Romain⁵,Abitbol Vered²,Laharie David⁶^ORCID,Reenaers Catherine⁷,Buisson Anthony⁸^ORCID,Pariente Benjamin⁹^ORCID,Viennot Stephanie¹⁰,Vuitton Lucine¹¹,Stefanescu Carmen¹²,Marteau Philippe²,Bouguen Guillaume¹³^ORCID,Cosnes Jacques²,Amiot Aurelien¹^ORCID,

Affiliation:

1. Creteil France

2. Paris France

3. Brussels Belgium

4. Lyon France

5. Montpellier France

6. Bordeaux France

7. Liège Belgium

8. Clermont-Ferrand France

9. Lille France

10. Besançon France

11. Caen France

12. Clichy France

13. Rennes France

Funder

Association François Aupetit

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14926/fullpdf

Reference47 articles.

1. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study;Feagan;Gastroenterology,2008

2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

3. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort;Gower-Rousseau;Gut,2017

4. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases;Amiot;Ther Adv Gastroenterol,2015

5. Crohn's disease: beyond antagonists of tumour necrosis factor;Peyrin-Biroulet;Lancet Lond Engl,2008

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study;Infection Prevention in Practice;2023-03

2. WHO Laboratory Biosafety Manual: A New Approach to Security;Annals of Work Exposures and Health;2022-12-10

3. Rheumatology expertise in advising immunocompromised healthcare workers: Insights from a survey of Australian rheumatologists;Infection, Disease & Health;2022-11

4. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2021-06

5. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease;Journal of Crohn's and Colitis;2021-03-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3